Biosimilars Watchlist
Drug status
Sandoz — Erelzi (Enbrel)
Court upholds Enbrel patents and a Sandoz is appealing.
Mylan — Ogivri (Herceptin)
Launched November 29, 2019
Teva/Celltrion — Herzuma (Herceptin)
Approved - most likely will launch in 1H2020
Merck/Samsung Bioepis — Ontruzant (Herceptin)
Approved - most likely will launch in 1H2020
Pfizer — Trazimera (Herceptin)
Launched February 15, 2020
Pfizer — Zirabev (Avastin)
Launched December 31, 2019
Pfizer — Ruxience (Rituxan)
Launched January 2020
Teva — Truxima (Rituxan)
Launched November 11, 2019
Tanvex — (Neupogen)
Received CRL from FDA
Sandoz — Ziextenzo (Neulasta)
Launched November 18, 2019